Sweden steps up rules against Russia's Baltic ‘shadow fleet'
STOCKHOLM: Sweden on Saturday announced new rules upping checks on foreign vessels in the Baltic from July 1, reinforcing a crackdown on Russia's 'shadow fleet' of tankers deployed to circumvent sanctions on its oil trade.
Since the Western-led sanctions imposed after its 2022 all-out invasion of Ukraine, Moscow has been relying on hundreds of such ships, that operate under murky ownership and dodgy insurance. European governments frequently blame the vessels for damaging — deliberately or not — undersea cables, and of posing a maritime environmental threat.
The Swedish government said in a statement that the new rules 'reinforce checks on foreign vessels by requiring insurance information'.
It said the effort 'aims to fight against this fleet and, in so doing, improve maritime safety and environmental protection'.
The Swedish coast guard and maritime authorities will be tasked with scrutinising insurance details not only of ships docking in Swedish ports, 'but also those crossing Swedish territorial waters, or its exclusive economic zone', which extends some 200 nautical miles from shore.
Sweden and Finland — both of whom recently joined NATO — are alert to Baltic Sea incidents impacting energy and communication infrastructure, after several instances of damage in late 2024.
'We are seeing a growing number of concerning incidents in the Baltic Sea, which requires... us to prepare for the worst,' Swedish Prime Minister Ulf Kristersson said in Saturday's statement.
He added that information gleaned under the new rules checking vessels would be shared with allies and could be added to databases used for sanctions enforcement.
The European Union last week adopted a 17th sanctions package against Russia that targets nearly 200 vessels in the 'shadow fleet'.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Recorder
30 minutes ago
- Business Recorder
UN nuclear chief urges ‘more transparency' from Iran
CAIRO: The UN atomic watchdog's chief on Monday called for more transparency from Iran as it seeks relief from sanctions in negotiations over its nuclear programme. International Atomic Energy Agency director general Rafael Grossi made the comments ahead of a meeting in Cairo with Iran's top diplomat and chief nuclear negotiator, Abbas Araghchi. It comes a day after a leaked IAEA report showed Iran has stepped up production of uranium enriched up to 60 percent – close to the roughly 90 percent level needed for atomic weapons. In a joint press conference with Egyptian Foreign Minister Badr Abdelatty before the scheduled tripartite meeting, Grossi defended the report, calling it 'impartial'. 'We say things as they are without a political agenda,' Grossi said, stressing the report 'tells it as it is'. Iran says official to meet UN nuclear chief on Monday 'There is a need for more transparency – this is very, very clear – in Iran, and nothing will bring us to this confidence (besides) full explanations of a number of activities,' he added. Iran has rejected the IAEA's findings, calling it a 'political' manouevre based on 'unreliable and misleading information'. Grossi said some of the report's findings 'may be uncomfortable for some, and we are… used to being criticised'. In a phone call with Grossi on Saturday, Araghchi warned Iran would retaliate if European powers that have threatened to reimpose nuclear sanctions 'exploit' the report. Abdelatty urged a peaceful solution, saying 'the region is already experiencing enough crises and security challenges'. 'We completely reject any escalation or incitement of a military option,' he said, warning against 'descending into a state of chaos from which no one will be spared'. The UN report comes as Iran holds talks with the United States on its nuclear programme, after Washington unilaterally abandoned a landmark agreement between Tehran and world powers in 2018 during President Donald Trump's first term. Iran on Monday demanded a US guarantee that sanctions will be lifted as part of a nuclear deal. The 2015 deal aimed to stop Iran from developing a nuclear bomb – a goal Western countries accused it of pursuing, though Tehran denies it. The Iranian foreign minister said Saturday he had received 'elements' of a US proposal for a potential nuclear deal following five rounds of Omani-mediated talks. The UN agency's board of governors is set to review Iran's nuclear activities in its upcoming quarterly meeting in Vienna starting June 9.
Express Tribune
an hour ago
- Express Tribune
Sanofi's $9.5B acquisition of Blueprint Medicines strengthens rare immunology portfolio
In a major move underscoring its ambition to lead in rare diseases and immunology, French pharmaceutical giant Sanofi announced its plan to acquire US-based Blueprint Medicines for up to $9.5 billion. The deal was announced by a press release on Sanofi's website. It is the largest by a European healthcare company this year and will see Sanofi paying $129 per share in cash, a significant premium that sent Blueprint's stock soaring in premarket trading. Blueprint Medicines, known for its specialty in treating systemic mastocytosis a rare blood disorder marked by the overproduction of mast cells brings to Sanofi a strong foothold in a niche yet critical area of medicine. The acquisition adds the FDA-approved drug Ayvakit, the only treatment for advanced systemic mastocytosis, to Sanofi's growing immunology portfolio. Sanofi CEO Paul Hudson framed the deal as a strategic leap forward, enhancing the company's pipeline and reinforcing its transformation into a global leader in immunology. We announced an agreement to acquire Blueprint Medicines, a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, and other KIT-driven diseases. — Sanofi (@sanofi) June 2, 2025 With a promising pipeline including next-generation therapies like elenestinib and BLU-808, the acquisition fits into Sanofi's broader ambition of innovation despite recent setbacks, including a failed lung disease drug trial. Industry analysts from JP Morgan praised the acquisition for its strategic and financial merits, forecasting Ayvakit could generate $2 billion in annual sales by 2030. Sanofi's ongoing spree of acquisitions, including Vigil Neuroscience and Inhibrx, signals a company doubling down on R&D investments to reshape its future. The acquisition aligns with Sanofi's broader strategy to invest heavily in US manufacturing and research, tapping into incentives and momentum driven by recent government policies. With Blueprint Medicines now joining its portfolio, Sanofi cements its stake in cutting-edge immunology treatments and rare disease therapies, positioning itself for long-term growth in a competitive pharmaceutical landscape.
Business Recorder
2 hours ago
- Business Recorder
Aluminium premiums for US buyers soars after Trump doubles tariffs
LONDON: Premiums for consumers buying aluminium on the physical market in the United States soared on Monday after U.S. President Donald Trump said he planned to increase tariffs on imported steel and aluminium to 50% from 25%. European industry hit hard by Trump tariffs, Salzgitter CEO warns The U.S. Midwest duty-paid aluminium premium reached $0.58 per lb, or $1,279 a metric ton, on Monday. That was a 54% jump from Friday.
